Indication for Use: The alfa pump® System is intended for single patient use only in adult patients with refractory or recurrent ascites due to liver cirrhosis. It is indicated for the removal of ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

This $250,000 grant is part of DDF's ongoing commitment to funding groundbreaking research that drives progress in the fight against gastric cancer. Since its founding, DDF has invested over $2 ...

Lighthouse Recovery, a leading drug and alcohol addiction treatment center in Dallas, Texas, is pleased to announce that it now accepts patients with Cigna insurance. This milestone represents a ...

In contrast to LVP, which provides only symptomatic control and requires repeated procedures, TIPS efficiently prevents the formation of ascites and increases urinary sodium excretion by reducing ...

Perhaps the ascites resulted from the swelling of the ... The unusual clinical course in this case is presented as a complication in the treatment of diabetic acidosis. It is hoped that this ...

While there’s no cure for autism, there are many approaches that can help both children and adults manage their symptoms and improve their quality of life. Autism spectrum disorder is a ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis The Company will be hosting a further webcast with key opinion ...

Recurrent or refractory ascites is a severe condition characterized by the accumulation of fluid in the abdomen. The current standard treatment involves therapeutic paracentesis, an invasive and ...

alfapump® is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosis US market opportunity estimated at ...